Loading
Latest filing published 21 Apr 2025 for Enfusion, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Kathleen DeRose in Enfusion, Inc., where the filings describe the role as board member. Between 31 October 2021 and 21 April 2025, the trades on record add up to 7 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The latest filing, published on 21 April 2025, reports a transaction in Enfusion, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations